



Prof méd. Oscar Matzinger

Spécialiste FMH Radio-oncologie

Profile

Languages

Français, suisse-allemand, allemand et anglais

Work experience

since 2019	Directeur médical en Radio-oncologie, Swiss Medical Network Chef de service des Services de Radio-oncologie, Clinique de Genolier et Centre d'Oncologie des Eaux-Vives, Genève
2016-2019	Chef de service, Service interdisciplinaire de Cancérologie, HRC (Unités d'Oncologie médicale, de Radio-oncologie, de Psycho-oncologie)
2013-2016	Médecin chef, Service de Radio-oncologie, Hôpital Riviera-Chablais (HRC)
2012	Médecin chef, Service a.i., CHUV
2011-2013	Médecin adjoint, Responsable des tumeurs gastro-intestinales, pulmonaires, cutanées et sarcomes, CHUV
2010-2011	Médecin associé, Responsable des tumeurs gastro-intestinales, pulmonaires, cutanées, CHUV
2009	Chef de clinique, Responsable des tumeurs gastro-intestinales, pulmonaires, cutanées, Service de Radio-oncologie, CHUV
2008-2009	Radiotherapy Quality Assurance Fellow, European Organisation of Research in Treatment of Cancer (EORTC), Bruxelles
2007-2008	Chef de clinique, Responsable des tumeurs ORL, poumon et mélanome, CHUV
2006	Chef de clinique adjoint, Service de Radio-oncologie, Inselspital
2005-2006	Médecin assistant en formation, Service de Radio-oncologie, Inselspital Berne
2002-2005	Médecin assistant en formation, Service de Radio-oncologie, CHUV
2001	Médecin assistant, Service d'Oncologie médicale, CHUV
2001-2002	Médecin assistant, Service de Radiologie, CHUV
2000-2001	Médecin assistant, Service de Médecine interne, CHUV
1999-2000	Médecin assistant, Institut de Physiologie de l'Université de Lausanne

Education

2015	Professeur Titulaire à l'Université de Lausanne (CHUV)
2011	GCP (Good Clinical Practice) certification niveau 3 (Reconnaissance Swiss medic)
2011	Privat Docent (PD) & Maître enseignement et de recherche (MER), Université de Lausanne

2006	Diplôme fédéral de spécialiste (titre FMH) en Radio-oncologie
2002	Doctorat en médecine, Université de Lausanne
1998	Examen fédéral médecine
1992-1998	Etudes de médecine, Faculté de médecine de Lausanne

Memberships

Politique professionnelle / autre

- Membre & secrétaire du comité exécutif SRO (Société Suisse de Radio-oncologie)
- Délégué tarifaire SRO
- Chairman de la conférence suisse des chefs de Service de Radio-oncologie
- Vice-président Ligue Vaudoise contre le Cancer (LVC)

Scientifique / clinique

- Membre du groupe de travail & expert office fédéral de la santé publique (OFSP)
- Audits cliniques de radioprotection des Services de Radio-oncologie suisse (2018 Audit du Service de Radio-oncologie du CHUV)
- Membre du comité et du comité scientifique «Fond'action contre le cancer»

Publications

2. Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, **Matzinger O**, Stojcheva N, Frueh M, Weder W, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters S; Swiss Group of Clinical Cancer Research (SAKK). Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). *Br J Cancer*. 2019 May;120(10):968-974. doi: 10.1038/s41416-019-0447-0.
2. Früh M M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein A, Schmid R, **Matzinger O**, Stahel RA, Weder W, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M; Multimodal Treatment in Operable Stage III Non-Small Cell Lung Cancer: A Pooled Analysis on Long Term Results of three SAKK trials (SAKK 16/96, 16/00, 16/01). *Swiss Group for Clinical Cancer Research (SAKK). J Thorac Oncol*. 2018 Sep 26. pii: S1556-0864(18)33123-X
2. Schernberg A, Rivin Del Campo E, Rousseau B, **Matzinger O**, Loi M, Maingon P, Huguet F. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. *Clin Transl Radiat Oncol*. 2018 Mar 13;10:13-22.
2. Santa Cruz O, Tsoutsou P, Castella C, Khanfir K, Anchisi S, Bouayed S, **Matzinger O**, Ozsahin M. Locoregional Control and Toxicity in Head and Neck Carcinoma Patients following Helical Tomotherapy-Delivered Intensity-Modulated Radiation Therapy Compared with 3D-CRT Data. *Oncology*. 2018;95(2):61-68.
2. De Bari B, Lestrade L, Franzetti-Pellanda A, Jumeau R, Biggiogero M, Kountouri M, **Matzinger O**, Miralbell R, Bourhis J, Ozsahin M, Zilli T. Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients. *J Cancer Res Clin Oncol*. 2018 Apr;144(4):781-789.

2. **Oscar Matzinger**, Solange Peters. Current Trends in Thoracic Radio-Oncology. Schweizer Krebsbulletin, 2017 June; 37(2): 148-155.

2. Lestrade L, Zilli T, Kountouri M, Jumeau R, **Matzinger O**, Bourhis J, Miralbell R, Ozsahin M, De Bari B. Early-stage Favourable Anal Cancer: A Retrospective Analysis of Clinical Outcomes of a Moderately Low Dose Elective Nodal Intensity-modulated Radiotherapy Schedule. Clin Oncol (R Coll Radiol). 2017 Jul;29(7):e105-e109.

2. Tsoutsou P, Annibaldi A, Viertl D, Ollivier J, Buchegger F, Vozenin MC, Bourhis J, Widmann C, **Matzinger O**. TAT-RasGAP317-326 Enhances Radiosensitivity of Human Carcinoma Cell Lines In Vitro and In Vivo through Promotion of Delayed Mitotic Cell Death. Radiat Res. 2017 May;187(5):562-569.

2. Kyroudi A, Petersson K, Ghandour S, Pachoud M, **Matzinger O**, Ozsahin M, Bourhis J, Bochud F, Moeckli R Discrepancies between selected Pareto optimal plans and final deliverable plans in radiotherapy multi-criteria optimization.. Radiother Oncol. 2016 Jun 3. pii: S0167-8140(16)31121-5

2. Ghandour S, Cosinschi A, Mazouni Z, Pachoud M, **Matzinger O**. Optimization of stereotactic body radiotherapy treatment planning using a multicriteria optimization algorithm. Z Med Phys. 2016 May 3. pii: S0939-3889(16)30004-6

2. De Bari B, Jumeau R, Bouchaab H, Vallet V, **Matzinger O**, Troussier I, Mirimanoff RO, Wagner AD, Hanhloser D, Bourhis J, Ozsahin EM. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients. Acta Oncol. 2016 Jun; 55(6):767-73

2. Ghandour S, **Matzinger O**, Pachoud M. Volumetric-modulated arc therapy planning using multicriteria optimization for localized prostate cancer. J Appl Clin Med Phys. 2015 May 8;16(3):5410

2. **Matzinger O**, Viertl D, Tsoutsou P, Kadi L, Rigotti S, Zanna C, Wiedemann N, Vozenin MC, Vuagniaux G, Bourhis J. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNF α -mediated in head and neck squamous cell carcinoma. Radiother Oncol. 2015 Jun 18. pii: S0167-8140(15)00270-4

2. Panje CM, Dal Pra A, Zilli T, R Zwahlen D, Papachristofilou A, Herrera FG, **Matzinger O**, Plasswilm L, Putora PM. Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland : A survey on patterns of practice. Strahlenther Onkol. 2015 May 19

2. Ugurluer G, Ballerini G, Moeckli R, **Matzinger O**, Bourhis J, Ozsahin M. Helical tomotherapy for the treatment of anal canal cancer: a dosimetric comparison with 3D conformal radiotherapy. *Tumori*. 2015 Jun 25;101(3):268-72

2. Casutt A, Bouchaab H, Beigelman-Aubry C, Bourhis J, Lovis A, **Matzinger O**. Stereotactic body radiotherapy with helical TomoTherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysis. *Br J Radiol*. 2015 May;88(1049):20140687. doi: 10.1259/bjr.20140687

2. Cosinschi A, Coskun M, Negretti L, **Matzinger O**, Jeanneret-Sozzi W, Vallet V, Moeckli R, Mirimanoff RO, Schiappacasse L, Ozsahin M, Bourhis J. A metastatic relapse associated with hippocampal dose sparing after whole-brain radiotherapy. *Acta Oncol*. 2014 Oct 3:1-3

2. Cai L, Mirimanoff RO, Mouhsine E, Guillou L, Leyvraz PF, Leyvraz S, Gay B, **Matzinger O**, Ozsahin M, Zouhair A. Prognostic factors in adult soft tissue sarcoma treated with surgery combined with radiotherapy: a retrospective single-center study on 164 patients. *Rare Tumors*. 2013 Oct 18;5(4):e55

2. Boujelbene N, Elloumi F, Kamel ME, Abeidi H, **Matzinger O**, Mirimanoff RO, Khanfir K. Stereotactic body radiation therapy in stage I inoperable lung cancer: from palliative to curative options. *Swiss Med Wkly*. 2013 May 28

2. Fenton PA, Hurkmans C, Gulyban A, van der Leer J, **Matzinger O**, Poortmans P, Collette L, Bolla M. Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: results of the Dummy Run procedure. *Radiother Oncol*. 2013 Jun;107(3):346-5

2. Gonzalez M, Litzistorf Y, Krueger T, Popeskou SG, **Matzinger O**, Ris HB, Gronchi F, Lovis A, Peters S. Impact of induction therapy on airway complications after sleeve lobectomy for lung cancer. *Ann Thorac Surg*. 2013 Jul;96(1):247-52

2. Joosten A, **Matzinger O**, Jeanneret-Sozzi W, Bochud F, Moeckli R. Evaluation of organ-specific peripheral doses after 2-dimensional, 3-dimensional and hybrid intensity modulated radiation therapy for breast cancer based on Monte Carlo and convolution/superposition algorithms: Implications for secondary cancer risk assessment. *Radiother Oncol*. 2013 Jan;106(1):33-41

2. Tsoutsou PG, Jeanneret Sozzi W, **Matzinger O**, Ozsahin M. Nomograms predicting locoregional recurrence in the subtype era of breast cancer. *J Clin Oncol*. 2013 Feb 10;31(5):647-8

2. Perentes J, Bopp S, Krueger T, Gonzalez M, Jayet PY, Lovis A, **Matzinger O**, Ruffieux C, Ris HB, Letovanec I, Peters S. Impact of lung function changes after induction radiochemotherapy on resected T4 non-small cell lung cancer outcome. *Ann Thorac Surg*. 2012 Dec;94(6):1815-22

2. Fairchild A, Aird E, Fenton PA, Gregoire V, Gulyban A, Lacombe D, **Matzinger O**, Poortmans P, Ruyskart P, Weber DC, Hurkmans CW. EORTC Radiation Oncology Group quality assurance platform: establishment of a digital central review facility. *Radiother Oncol*. 2012 Jun;103(3):279-86

2. Rossier C, Dunet V, **Matzinger O**, Prior JO. PET/CT and radiotherapy: indications and potential applications. *Cancer Radiother*. 2012 Apr;16(2):152-63

2. Ozsahin M, Santa Cruz O, Bouchaab H, **Matzinger O**, Tsoutsou PG. Definitive organ-sparing treatment of anal canal cancer: can we afford to question it? *J Clin Oncol*. 2012 Feb 20;30(6):673-4; 674-5

2. Tsoutsou PG, Sozzi WJ, **Matzinger O**, Ozsahin M. Personalizing Locoregional Treatment in the Adjuvant Setting of Early Breast Cancer on the Basis of Molecular Background: An Exciting Enigma. *J Clin Oncol*. 2011 Dec 10;29(35):4721-4722

2. Khanfir K, Elhfidh M, Anchisi S, **Matzinger O**, Bieri S, Mirimanoff RO, Ozsahin M, Zouhair A. Sequential or concomitant chemotherapy in limited stage small-cell lung cancer. *Swiss Med Wkly*. 2011 May 31

2. Gonzalez M, Krueger T, Perentes JY, **Matzinger O**, Peters S, Ris HB. Extrapleural pneumonectomy with venous confluence resection for stage IVA thymic tumors. *Ann Thorac Surg* 2011;91:941-943

2. Zouhair A, **Matzinger O**, Azria D, Gaye MP, Ugurluer G, El Hfid M, Mirimanoff RO, Ozsahin M. Post-operative radiochemotherapy of the head and neck: Towards new standards? *Cancer Radiother* 2010;14:217-221

2. Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, Azria D, Roelandts M, Kaanders JH, Cengiz M, Krengli M, **Matzinger O**, Zouhair A. Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. *Int J Radiat Oncol Biol Phys* 2010;78:992-997

2. **Matzinger O**, Heimsoth I, Poortmans P, Collette L, Struikmans H, Van Den Bogaert W, Fourquet A, Bartelink H, Ataman F, Gulyban A, Pierart M, Van Tienhoven Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925). *Acta Oncol* 2010;49:24-34

2. Pehlivan B, Zouhair A, Luthi F, Bron L, Pasche P, Dragusanu D, Azria D, **Matzinger O**, Mirimanoff RO, Ozsahin M. Decrease in hemoglobin levels following surgery influences the outcome in head and neck cancer patients treated with accelerated postoperative radiotherapy. *Ann Surg Oncol* 2009;16:1331-1336

2. Pehlivan B, Luthi F, **Matzinger O**, Betz M, Dragusanu D, Bulling S, Bron L, Pasche P, Seelentag W, Mirimanoff RO, Zouhair A, Ozsahin M. Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer. *Ann Surg Oncol* 2009;16:1337-1343

2. **Matzinger O**, Zouhair A, Mirimanoff RO, Ozsahin M. Radiochemotherapy in locally advanced squamous cell carcinomas of the head and neck. *Clin Oncol (R Coll Radiol)* 2009;21:525-531

2. **Matzinger O**, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, Haustermans K, Radosevic-Jelic L, Mueller RP, Maingon P, Collette L, Bosset JF. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). *Eur J Cancer* 2009;45:2782-2791

2. **Matzinger O**, Poortmans P, Giraud JY, Maingon P, Budiharto T, van den Bergh AC, Davis JB, Musat E, Ataman F, Huyskens DP, Gulyban A, Bolla M. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review. *Radiother Oncol* 2009;90:285-290

2. **Matzinger O**, Gerber E, Bernstein Z, Maingon P, Haustermans K, Bosset JF, Gulyban A, Poortmans P, Collette L, Kuten A. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. *Radiother Oncol* 2009;92:164-175

2. **Matzinger O**, Duclos F, van den Bergh A, Carrie C, Villa S, Kitsios P, Poortmans P, Sundar S, van der Steen-Banasik EM, Gulyban A, Collette L, Bolla M. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. *Eur J Cancer* 2009;45:2825-2834

2. Ghadjar P, **Matzinger O**, Isaak B, Behrensmeier F, Stroux A, Rentsch CA, Thalmann GN, Aebersold DM. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. *Radiother Oncol* 2009;91:237-242

2. Ozsahin M, **Matzinger O**, Zimmermann M, Zouhair A. Radio-chemotherapy in head and neck cancer (EGFR+). *Bull Cancer* 2007;94:828-832

2. Ozsahin M, Betz M, **Matzinger O**, Bron L, Luthi F, Pasche P, Azria D, Mirimanoff RO, Zouhair A. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. *Arch Otolaryngol Head Neck Surg* 2006;132:141-145

2. Coucke PA, Notter M, Stamm B, Matter M, Fasolini F, Schlumpf R, **Matzinger O**, Bouzourene H. Preoperative hyper-fractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC) immediately followed by surgery. A prospective phase II trial. *Radiother Oncol* 2006;79:52-58

2. **Matzinger O**. Working conditions regulated by in-training Swiss physicians: one year of experience. *Rev Med Suisse*. 2006 Oct 18;2(83):2365-8

2. Frei A, de Vevey P, Kiefer B, Giorgis B, Jaquet JL, Pilet F, **Matzinger O**. Manifesto on "Health politics: stop the scuttling!": to (almost) conclude. *Rev Med Suisse*. 2005 Mar 16;1(11):790-2.

2. Delaloye J, Merlani G, Petignat C, Wenger A, Zaman K, Monnerat C, **Matzinger O**, Beck Popovic M, Vuichard P, Ketterer N, Tarr PE. Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization? *Eur J Clin Microbiol Infect Dis*. 2004 Oct;23(10):751-8

2. Michielin O, Udry E, Periard D, **Matzinger O**, Lobrinus JA, Stupp R. Irinotecan-induced interstitial pneumonia. *Lancet Oncol*. 2004 May;5(5):322-4

2. Zouhair A, Azria D, Coucke P, **Matzinger O**, Bron L, Moeckli R, Do HP, Mirimanoff RO, Ozsahin M. Decreased local control following radiation therapy alone in early-stage glottic carcinoma with anterior commissure extension. *Strahlenther Onkol.* 2004 Feb;180(2):84-90

2. Coucke PA, Jichliski P, **Matzinger O**, Ozsahin M, Bulling SM, Zouhair A. Antiandrogen gynecomastia: an inescapable harm? Radiotherapy: a simple and efficient solution! *Rev Med Suisse Romande.* 2004 Jan;124(1):51-4

2. Henchoz E, D'Alessio DA, Gillet M, Halkic N, **Matzinger O**, Goy JJ, Chioléro R, Tappy L, Schneiter P. Impaired insulin response after oral but not intravenous glucose in heart- and liver-transplant recipients. *Transplantation.* 2003 Sep 27;76(6):923-9

2. Delarue J, **Matzinger O**, Binnert C, Schneiter P, Chioléro R, Tappy L. Fish oil prevents the adrenal activation elicited by mental stress in healthy men. *Diabetes Metab.* 2003 Jun;29(3):289-95

2. **Matzinger O**, Schneiter P, Tappy L. Effects of fatty acids on exercise plus insulin-induced glucose utilization in trained and sedentary subjects. *Am J Physiol Endocrinol Metab.* 2002 Jan;282(1):E125-31

4. Rigalleau V, Binnert C, Minehira K, Stefanoni N, Schneiter P, Henchoz E, **Matzinger O**, Cayeux C, Jéquier E, Tappy L. In normal men, free fatty acids reduce peripheral but not splanchnic glucose uptake. *Diabetes.* 2001 Apr;50(4):727-32

Accreditation

[Clinique de Genolier](#)

[Clinique Générale-Beaulieu](#)

[Centre médical des Eaux-Vives](#)

Specialties

[Radiation oncology / Radiotherapy](#)

Contact

Clinique de Genolier
Route du Muids 3
1272 Genolier

T +41 22 366 94 59

[Download vCard](#)

Centre d'oncologie des Eaux-Vives
Rue Maunoir 26
1207 Genève

T +41 22 319 77 77

[Download vCard](#)